GlassScriptPhysician profile
Surendra Chaganti
NPI 1932213725
$2,827.90
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,768 · 2020: $796 · 2021: $264.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $1,333.79 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $279.57 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $221.43 | 2019-2020 | |
| Allergan, INC. | $204.34 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $185.15 | 2021 | |
| Indivior INC. | $179.30 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $135.51 | 2019 | |
| Alkermes, INC. | $112.04 | 2019-2021 | |
| Lundbeck LLC | $68.66 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.47 | 2019 | |
| Neurocrine Biosciences, INC. | $35.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.09 | 2019 | |
| Shire North American Group INC | $11.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Surendra Chaganti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.